{"id":"https://openalex.org/W2016994976","doi":"https://doi.org/10.1097/01.hjh.0000220403.61493.18","title":"Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans","display_name":"Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans","alternate_titles":[],"publication_year":2006,"publication_date":"2006-03-01","ids":{"openalex":"https://openalex.org/W2016994976","doi":"https://doi.org/10.1097/01.hjh.0000220403.61493.18","mag":"2016994976","pmid":"https://pubmed.ncbi.nlm.nih.gov/16601569"},"language":"en","primary_location":{"id":"doi:10.1097/01.hjh.0000220403.61493.18","doi":"https://doi.org/10.1097/01.hjh.0000220403.61493.18","is_oa":false,"landing_page_url":"https://doi.org/10.1097/01.hjh.0000220403.61493.18","pdf_url":null,"source":{"id":"https://openalex.org/S115964404","display_name":"Journal of Hypertension","issn_l":"0263-6352","issn":["0263-6352","1473-5598"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Hypertension","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2016994976"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065113357","display_name":"Georges Vauquelin","orcid":"https://orcid.org/0000-0001-8613-1711","observed_orcids":["https://orcid.org/0000-0001-8613-1711"]},"institutions":[{"id":"https://openalex.org/I13469542","display_name":"Vrije Universiteit Brussel","ror":"https://ror.org/006e5kg04","country_code":"BE","type":"education","lineage":["https://openalex.org/I13469542"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Georges Vauquelin","raw_affiliation_strings":["Department of Molecular and Biochemical Pharmacology, Free University of Brussels (VUB), Brussels, Belgium. gvauquel@vub.ac.be","Department of Molecular and Biochemical Pharmacology, Free University of Brussels (VUB), Brussels, Belgium","amd requests for reprints to Prof. Georges Vauquelin, Department of Molecular and Biochemical Pharmacology, Building E.5.10, Vrije Universiteit Brussel (VUB), Pleinlaan 2, B-1050 Brussels, Belgium Tel: +32 2 6291955","e-mail: [email\u00a0protected]","fax: +32 2 6291358"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Molecular and Biochemical Pharmacology, Free University of Brussels (VUB), Brussels, Belgium. gvauquel@vub.ac.be","institution_ids":["https://openalex.org/I13469542"]},{"raw_affiliation_string":"Department of Molecular and Biochemical Pharmacology, Free University of Brussels (VUB), Brussels, Belgium","institution_ids":["https://openalex.org/I13469542"]},{"raw_affiliation_string":"amd requests for reprints to Prof. Georges Vauquelin, Department of Molecular and Biochemical Pharmacology, Building E.5.10, Vrije Universiteit Brussel (VUB), Pleinlaan 2, B-1050 Brussels, Belgium Tel: +32 2 6291955","institution_ids":["https://openalex.org/I13469542"]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"fax: +32 2 6291358","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061469672","display_name":"Frederik L. P. Fierens","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I13469542","display_name":"Vrije Universiteit Brussel","ror":"https://ror.org/006e5kg04","country_code":"BE","type":"education","lineage":["https://openalex.org/I13469542"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Frederik Fierens","raw_affiliation_strings":["Department of Molecular and Biochemical Pharmacology, Free University of Brussels (VUB), Brussels, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Molecular and Biochemical Pharmacology, Free University of Brussels (VUB), Brussels, Belgium","institution_ids":["https://openalex.org/I13469542"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5084125169","display_name":"Isabelle Van Liefde","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I13469542","display_name":"Vrije Universiteit Brussel","ror":"https://ror.org/006e5kg04","country_code":"BE","type":"education","lineage":["https://openalex.org/I13469542"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Isabelle Van Liefde","raw_affiliation_strings":["Department of Molecular and Biochemical Pharmacology, Free University of Brussels (VUB), Brussels, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Molecular and Biochemical Pharmacology, Free University of Brussels (VUB), Brussels, Belgium","institution_ids":["https://openalex.org/I13469542"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5065113357"],"corresponding_institution_ids":["https://openalex.org/I13469542"],"apc_list":null,"apc_paid":null,"fwci":2.3238,"has_fulltext":false,"cited_by_count":49,"citation_normalized_percentile":{"value":0.88536202,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":98},"biblio":{"volume":"24","issue":"Suppl 1","first_page":"S23","last_page":"S30"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.9711999893188477,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.9711999893188477,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11178","display_name":"Receptor Mechanisms and Signaling","score":0.022199999541044235,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12910","display_name":"Eicosanoids and Hypertension Pharmacology","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/candesartan","display_name":"candesartan","score":0.9300000071525574},{"id":"https://openalex.org/keywords/angiotensin-type-1-receptor-antagonists","display_name":"angiotensin type 1 receptor antagonists","score":0.925000011920929},{"id":"https://openalex.org/keywords/receptor-dissociation-rate","display_name":"receptor dissociation rate","score":0.6449999809265137},{"id":"https://openalex.org/keywords/insurmountable-antagonism","display_name":"insurmountable antagonism","score":0.8830000162124634},{"id":"https://openalex.org/keywords/receptor-occupancy","display_name":"receptor occupancy","score":0.699999988079071},{"id":"https://openalex.org/keywords/angiotensin-ii","display_name":"angiotensin II","score":0.8420000076293945},{"id":"https://openalex.org/keywords/valsartan","display_name":"valsartan","score":0.996999979019165},{"id":"https://openalex.org/keywords/irbesartan","display_name":"irbesartan","score":0.9990000128746033},{"id":"https://openalex.org/keywords/losartan","display_name":"losartan","score":0.9039999842643738}],"concepts":[{"id":"https://openalex.org/C2780036600","wikidata":"https://www.wikidata.org/wiki/Q415970","display_name":"Candesartan","level":4,"score":0.7998663187026978},{"id":"https://openalex.org/C2780288358","wikidata":"https://www.wikidata.org/wiki/Q410074","display_name":"Losartan","level":4,"score":0.7120382189750671},{"id":"https://openalex.org/C2908929049","wikidata":"https://www.wikidata.org/wiki/Q65963433","display_name":"Angiotensin II","level":3,"score":0.704110860824585},{"id":"https://openalex.org/C123915805","wikidata":"https://www.wikidata.org/wiki/Q15332826","display_name":"Angiotensin II receptor type 1","level":4,"score":0.6631908416748047},{"id":"https://openalex.org/C2777387769","wikidata":"https://www.wikidata.org/wiki/Q155472","display_name":"Valsartan","level":3,"score":0.5740135312080383},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.5338038206100464},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5234046578407288},{"id":"https://openalex.org/C2778122271","wikidata":"https://www.wikidata.org/wiki/Q410943","display_name":"Receptor antagonist","level":4,"score":0.4852883517742157},{"id":"https://openalex.org/C104849204","wikidata":"https://www.wikidata.org/wiki/Q24778533","display_name":"Angiotensin receptor","level":4,"score":0.4528135657310486},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.41219577193260193},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4003564119338989},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3500427007675171},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.3401760458946228},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D001562","descriptor_name":"Benzimidazoles","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D001562","descriptor_name":"Benzimidazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D001713","descriptor_name":"Biphenyl Compounds","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003198","descriptor_name":"Computer Simulation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D044140","descriptor_name":"Receptor, Angiotensin, Type 1","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D047228","descriptor_name":"Angiotensin II Type 1 Receptor Blockers","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D047228","descriptor_name":"Angiotensin II Type 1 Receptor Blockers","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1097/01.hjh.0000220403.61493.18","doi":"https://doi.org/10.1097/01.hjh.0000220403.61493.18","is_oa":false,"landing_page_url":"https://doi.org/10.1097/01.hjh.0000220403.61493.18","pdf_url":null,"source":{"id":"https://openalex.org/S115964404","display_name":"Journal of Hypertension","issn_l":"0263-6352","issn":["0263-6352","1473-5598"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Hypertension","raw_type":"journal-article"},{"id":"pmid:16601569","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16601569","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","raw_type":"Comparative Study"},{"id":"pmh:oai:vubissmart:VUBISSMART:2000:35025","doi":null,"is_oa":false,"landing_page_url":"https://biblio.vub.ac.be/vubir/longlasting-at1-receptor-binding-and-protection-by-candesartan-comparison-to-other-biphenyltetrazole-sartans(5718d2d8-ed29-42cb-b8fb-ace1a0c08ea2).html","pdf_url":null,"source":{"id":"https://openalex.org/S4306402573","display_name":"VUBIR (Vrije Universiteit Brussel)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I13469542","host_organization_name":"Vrije Universiteit Brussel","host_organization_lineage":["https://openalex.org/I13469542"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"article"},{"id":"mag:3130398028","doi":null,"is_oa":false,"landing_page_url":"https://researchportal.vub.be/en/publications/long-lasting-at1-receptor-binding-and-protection-by-candesartan-c","pdf_url":null,"source":{"id":"https://openalex.org/S115964404","display_name":"Journal of Hypertension","issn_l":"0263-6352","issn":["0263-6352","1473-5598"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Journal of Hypertension","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.8371999859809875,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":54,"referenced_works":["https://openalex.org/W35597192","https://openalex.org/W137606157","https://openalex.org/W1749934866","https://openalex.org/W1891552192","https://openalex.org/W1911560968","https://openalex.org/W1965521882","https://openalex.org/W1974959226","https://openalex.org/W1976633810","https://openalex.org/W1979535634","https://openalex.org/W1985042283","https://openalex.org/W1998126138","https://openalex.org/W1999181065","https://openalex.org/W2002994521","https://openalex.org/W2009802672","https://openalex.org/W2016686407","https://openalex.org/W2017561701","https://openalex.org/W2020304135","https://openalex.org/W2023077221","https://openalex.org/W2024179544","https://openalex.org/W2027521314","https://openalex.org/W2029653823","https://openalex.org/W2031418023","https://openalex.org/W2033749858","https://openalex.org/W2035737952","https://openalex.org/W2052331738","https://openalex.org/W2054479029","https://openalex.org/W2056267722","https://openalex.org/W2061743585","https://openalex.org/W2067946831","https://openalex.org/W2074008057","https://openalex.org/W2076345901","https://openalex.org/W2080697422","https://openalex.org/W2089698436","https://openalex.org/W2091261382","https://openalex.org/W2092171289","https://openalex.org/W2092556644","https://openalex.org/W2095775529","https://openalex.org/W2101780854","https://openalex.org/W2104137617","https://openalex.org/W2116259845","https://openalex.org/W2117178285","https://openalex.org/W2120331575","https://openalex.org/W2122428188","https://openalex.org/W2125256919","https://openalex.org/W2126278865","https://openalex.org/W2134899427","https://openalex.org/W2144335239","https://openalex.org/W2145879452","https://openalex.org/W2159823385","https://openalex.org/W2289785680","https://openalex.org/W2321787823","https://openalex.org/W2362789409","https://openalex.org/W6601448900","https://openalex.org/W6639339015"],"related_works":["https://openalex.org/W2101780854","https://openalex.org/W2009802672","https://openalex.org/W2168834946","https://openalex.org/W2023077221","https://openalex.org/W137606157","https://openalex.org/W321430196","https://openalex.org/W2027521314","https://openalex.org/W2005588489","https://openalex.org/W1999181065"],"abstract_inverted_index":{"BACKGROUND:":[0],"The":[1,89,174],"ability":[2],"of":[3,69,84,91,100,122,130,161,212],"biphenyl-tetrazole":[4],"angiotensin":[5,14],"type":[6],"1":[7],"(AT1)":[8],"receptor":[9,184,228,243],"antagonists":[10,157,207,215],"(BTsartans)":[11],"to":[12,47,66,81,124,137,149,168,236,240],"block":[13],"II":[15,44],"(Ang":[16],"II)-mediated":[17],"responses":[18],"has":[19],"been":[20],"extensively":[21],"investigated":[22],"in":[23,29,104,222,238],"vascular":[24],"tissues":[25],"and,":[26],"more":[27],"recently,":[28],"cell":[30],"lines":[31],"expressing":[32],"the":[33,42,48,54,67,74,82,94,97,101,105,151,187,198,209],"human":[34],"AT1-receptor.":[35],"When":[36],"pre-incubated,":[37],"BTsartans":[38,102,131],"acted":[39],"surmountably":[40],"(shifting":[41],"Ang":[43],"concentration-response":[45],"curve":[46],"right)":[49],"or":[50],"insurmountably":[51],"(also":[52],"decreasing":[53],"maximal":[55],"response).":[56],"It":[57,120],"was":[58],"shown":[59],"that":[60,177],"their":[61,138],"insurmountable":[62,77,92,206,214],"behaviour":[63],"is":[64,79,121,190,197],"due":[65,80],"formation":[68],"tight,":[70],"long-lasting":[71,139,242],"complexes":[72],"with":[73,171],"receptor.":[75],"Partial":[76],"antagonism":[78],"co-existence":[83],"tight":[85,127],"and":[86,96,153,205,230],"loose":[87],"complexes.":[88],"proportion":[90],"antagonism,":[93],"potency":[95],"dissociation":[98,179,229],"rate":[99],"decreases":[103],"order:":[106],"candesartan":[107,134],">":[108,113,115],"EXP3174":[109],"(losartan's":[110],"active":[111],"metabolite)":[112],"valsartan":[114],"irbesartan":[116],">>":[117],"losartan.":[118],"OBJECTIVE:":[119],"interest":[123],"explore":[125],"how":[126],"AT1-receptor":[128],"binding":[129],"such":[132],"as":[133,158],"might":[135],"contribute":[136],"clinical":[140],"effect.":[141],"METHODS:":[142],"Computer-assisted":[143],"simulations":[144,175],"(COPASI":[145],"program)":[146],"were":[147,166],"performed":[148],"follow":[150],"receptor-occupation":[152],"protection":[154,219],"by":[155],"different":[156],"a":[159,193],"function":[160],"time.":[162,172],"Free":[163],"antagonist":[164,189,232],"concentrations":[165],"allowed":[167],"decrease":[169],"exponentially":[170],"RESULTS:":[173],"suggest":[176],"slow":[178,231],"does":[180],"not":[181],"tangibly":[182],"prolong":[183],"occupancy":[185],"if":[186],"free":[188],"eliminated":[191],"at":[192],"slower":[194],"pace":[195],"(as":[196],"case":[199],"for":[200],"BTsartans).":[201],"Yet":[202],"when":[203],"surmountable":[204],"occupy":[208],"same":[210],"amount":[211],"receptors,":[213],"offer":[216],"appreciably":[217],"better":[218],"against":[220],"fluctuations":[221],"natural":[223],"messenger":[224],"concentration.":[225],"CONCLUSION:":[226],"Slow":[227],"elimination":[233],"are":[234],"likely":[235],"act":[237],"synergy":[239],"produce":[241],"protection.":[244]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2016994976","counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":5},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
